Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-05-17
1995-06-27
Russel, Jeffrey E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
424 854, 4241931, 4241941, 514 2, 514 4, 514 6, 514 12, 514 15, 514 52, 530303, 530306, 530313, 530345, 530351, 530398, 530399, 530405, 530409, 536 264, 536 2641, 536 2644, A61K 3168, A61K 3841, C07H 2300, C07K 1113
Patent
active
054280230
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to oral delivery systems. More particularly the invention relates to enhancing the absorption of active substances by administering these substances bound to vitamin B12 (VB12) or an analogue thereof.
BACKGROUND ART
The oral route of administration is perhaps the most preferable means of delivering an antigen or pharmaceutically active agent to man. This route does however suffer from the major disadvantage that there is generally poor uptake of antigens or pharmaceutically active agents by the gastrointestinal tract and some agents may be destroyed by prolonged exposure to proteolytic enzymes. In this regard, attemps to orally immunize man or animals in the past have met with limited success. Effective vaccination has generally only been achieved by the administration of large quantities of antigen or by combining parenteral priming with oral boosting. Recent work by us utilizing a number of molecules with the ability to bind to the intestinal mucosa has demonstrated effective oral immunization using low doses of these binding proteins or by coupling various antigens or haptens to these carriers. Uptake and delivery to the circulation of these molecules from the intestine seemed to be due to receptor mediated endocytosis.
It has been known for some time that a number of specific uptake mechanisms exist in the gut for uptake of dietary molecules. Thus there are specific uptake mechanisms for monosaccharides, disaccharides, amino acids and vitamins. Most of these uptake mechanisms depend upon the presence of a specific protein or enzyme such as monosaccharidase or disaccharidase situated in the mucosal lamina propria which binds to the molecule and transports it into the cells lining and lamina propria.
Two notable exceptions to these uptake mechanisms are found with iron transport and VB12 uptake. In both these cases a specific binding protein is released into the intestine, which binds to its ligand in the lumen of the gut.
Thus, during iron uptake in the intestine transferrin is released from the stomach, binds to iron and is in turn bound by a receptor on the duodenal mucosa. The receptor-transferrin-iron complex is then taken up by receptor mediated endocytosis.
Similarly, the absorption of physiological amounts of VB12 by the gut requires that it be complexed with a naturally occurring transport protein known as intrinsic factor (IF) (1-5). This protein is released into the lumen of the stomach by parietal cells in the fundus. Once bound to intrinsic factor, the VB12.IF complex interacts with a membrane bound receptor for IF located on the terminal ileum of the small intestine. The receptor-IF-VB12 complex is then internalized by a process of receptor mediated endocytosis (RME). Allen and Majerus (7) demonstrated that it is possible to chemically modify VB12, couple it to a resin and use the VB12-resin to affinity purify IF. This finding suggested to us that it may be possible to couple large macromolecules (such as the resin used by Allen and Majerus) to VB12 and to still preserve it's ability to interact specifically with intrinsic factor. By coupling molecules to VB12 in such a way as to preserve the ability of VB12 to interact with intrinsic factor it was hoped that we could use the natural uptake mechanism for VB12, to deliver various proteins, drugs or other pharmaceutically active molecules to the circulation.
It is thus the object of this invention to utilize the VB12 uptake mechanism to transport active substances such a drugs, hormones, antigenic material and the like, covalently coupled to VB12 or an analogue thereof, from the intestinal lumen into the circulation.
DISCLOSURE OF THE INVENTION
In a first embodiment the invention provides a complex which comprises at least one active substance linked to at least one carrier molecule which is VB12 or an analogue thereof wherein the ability of the carrier to undergo the binding reactions necessary for uptake and transport of VB12 in a vertebrate host and the activity of the active substance a
REFERENCES:
patent: 3042588 (1962-07-01), Heathcote
patent: 3459855 (1969-08-01), Thuiller
patent: 3920631 (1975-11-01), Molteni et al.
patent: 3981863 (1976-09-01), Niswender et al.
patent: 4133951 (1979-01-01), Charlton et al.
patent: 4209614 (1980-06-01), Bernstein et al.
patent: 4235866 (1980-11-01), Thoma
patent: 4360358 (1982-11-01), Sharma
patent: 4364939 (1982-12-01), Autissier et al.
patent: 4452775 (1984-06-01), Kent
patent: 4454125 (1984-06-01), Demopoulos
patent: 4465775 (1984-08-01), Houts
patent: 4508832 (1985-04-01), Carter et al.
patent: 4746508 (1988-05-01), Carey et al.
patent: 4751285 (1988-06-01), Toohey
Bloom et al., Mount Sinai J. Medicine, vol. 48, No. 5 pp. 397-403 (1981).
Biochemistry, vol. 23, Issued 1984, Elsenhans et al., "Influence of Metal Substitution on Vitamin B12 Binding . . . ", pp. 805-808.
Grant, ed., Hackh's Chemical Dictionary, 4th ed., Published 1969 by McGraw-Hill Book Co. (N.Y.), pp. 192, 715.
Albert, A., "Heterocyclic Chemistry", p. 143 (1959).
Laurence, G. S., Trans. Faraday Soc. vol. 52, pp. 236-242 (1955).
Sillen, L. G. and Martell, A. E., "Stability Constants of Metal Ion Complexes", Chem. Soc. Special Publication No. 17 pp. iii, v, vii, 1, and 357 (1964).
Wallenfels, K. and Streffer, C., Biochem. Zeit., vol. 346, pp. 119-132 (1966).
English Translation of Swiss Patent 0,467,277.
English Translation of Hamada, S., J. Chem. Soc. Japan 82 1327 (1961).
"Autoradiographic Study of Sugar and Amino Acid Absorption by Everted Sacs of Hamster Intestine", W. B. Kinter, Ph.D., and T. H. Wilson, M.D., The Journal of Cell Biology, vol. 25, pp. 19-39, 1965.
"Progress in Gastroenterology:Peptide Absorption", Gastroenterol, vol. 71:151-161, D. M. Mathews, and S. A. Adibi, 1976.
"Uptake and Fate of Absorbed Amino Acids and Peptides in the Mammalian Intestine", D. H. Alpers, Fed. Proc., vol. 45, pp. 2261-2267.
"Kinetics and Characteristics of Absorption From an Equimolar Mixture of 12 Glycyl-Dipeptides in Human Jejunum", H. J. Steinhardt and S. A. Adibi, Gastroenterol, vol. 90, pp. 577-582, 1986.
"Amino Acid Concentrations in Portal Venous Plasma During Absorption from the Small Intestine of the Guinea Pig of an Amino Acid Mixture Simulation Casein and a Partial Enzymic Hydrolysate of Casein", M. H. Sleisenger, D. Pelling, D. Burston and D. M. Matthews, Clinical Science and Molecular Medicine, vol. 52, pp. 259-267, 1977.
"Protein Digestion and Absorption in Human Small Intestine", Gastroenterol, Y. C. Chung, Y. S. Kim, A. Shadchehr, A. Garrido, I. L. MacGregor, and M. H. Sleisenger, vol. 76, pp. 1415-1471, 1979.
"Peptide Absorption and Hydrolysis" Physiology of the Gastrointestinal Tract, pp. 1073-1095, S. A. Adibi and Y. S. Kim, 1987.
"Some Biological Issues in Oral, Controlled Drug Delivery", Adv. Drug Delivery Rev., P. Gruber, M. A. Longer, and J. R. Robinson, vol. 1, pp. 1-18, 1987.
Burge Geoffery L.
de Aizpurua Henry J.
Howe Peter
Russell-Jones Gregory J.
Biotechnology Australia Pty. Ltd.
Russel Jeffrey E.
LandOfFree
Oral delivery of biologically active substances bound to vitamin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oral delivery of biologically active substances bound to vitamin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral delivery of biologically active substances bound to vitamin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-287572